SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Mu, Ping; Zhang, Zeda; Benelli, Matteo; Karthaus, Wouter R; Hoover, Elizabeth; Chen, Chi-Chao; Wongvipat, John; Ku, Sheng-Yu; Gao, Dong; Cao, Zhen; Shah, Neel; Adams, Elizabeth J; Abida, Wassim; Watson, Philip A; Prandi, Davide; Huang, Chun-Hao; de Stanchina, Elisa; Lowe, Scott W; Ellis, Leigh; Beltran, Himisha; ... (2017). SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science, 355(6320), pp. 84-88. American Association for the Advancement of Science 10.1126/science.aah4307

Text 84.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Some cancers evade targeted therapies through a mechanism known as lineage plasticity, whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no longer depends on the drug target. We use in vitro and in vivo human prostate cancer models to show that these tumors can develop resistance to the antiandrogen drug enzalutamide by a phenotypic shift from androgen receptor (AR)-dependent luminal epithelial cells to AR-independent basal-like cells. This lineage plasticity is enabled by the loss of TP53 and RB1 function, is mediated by increased expression of the reprogramming transcription factor SOX2, and can be reversed by restoring TP53 and RB1 function or by inhibiting SOX2 expression. Thus, mutations in tumor suppressor genes can create a state of increased cellular plasticity that, when challenged with antiandrogen therapy, promotes resistance through lineage switching.

Interest & Impact

Downloads

2 since deposited on 08 Mar 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item